GlassScriptPhysician profile
Thomas M Demoor
NPI 1447225982
$4,705.77
in general payments reported to CMS, 2019-2025
17 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 87% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $157 · 2022: $991 · 2023: $538 · 2024: $953 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,133.70 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $748.47 | 2019-2025 | Rexulti |
| Corium, LLC | $522.35 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $431.01 | 2022-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $332.95 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $327.17 | 2019-2023 | Jornay Pm |
| Abbvie INC. | $253.72 | 2022-2025 | Vraylar |
| Lundbeck LLC | $179.55 | 2020-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $143.63 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $141.85 | 2019 | |
| Allergan, INC. | $124.99 | 2020 | |
| Axsome Therapeutics, INC. | $124.36 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $101.23 | 2022 | |
| Shire North American Group INC | $51.21 | 2019 | |
| Neos Therapeutics, LP | $38.13 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.45 | 2020-2022 | |
| Tris Pharma INC | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Demoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.